Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and risk of colon and rectal cancer: Additional support for a TGF-β-signaling pathway

Carcinogenesis

Volumn 32, Issue 3, 2011, Pages 318-326

  Slattery, Martha L ^a   Lundgreen, Abbie ^a   Herrick, Jennifer S ^a   Caan, Bette J ^b   Potter, John D ^c   Wolff, Roger K ^a  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b KAISER PERMANENTE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER RISK; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MICROSATELLITE INSTABILITY; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RECTUM CANCER; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952288107     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq245     Document Type: Article

References (39)

1. Lund,A.H. et al. (2002) RUNX: a trilogy of cancer genes. Cancer Cell, 1, 213-215.
2. Anglin,I. et al. (2004) Runx protein signaling in human cancers. Cancer Treat. Res., 119, 189-215.
3. Bangsow,C. et al. (2001) The RUNX3 gene-sequence, structure and regulated expression. Gene, 279, 221-232.
4. Blyth,K. et al. (2005) The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer, 5, 376-387.
5. Zhu,B. et al. (2007) Transforming Growth Factor-B and Cancer. John Wiley & Sons, Ltd, San Francisco, CA.
6. Coffman,J.A. (2003) Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol. Int., 27, 315-324.
7. Ito,Y. et al. (2003) RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr. Opin. Genet. Dev., 13, 43-47.
8. Lee,K.S. et al. (2002) Both the Smad and p38MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factorbeta and bone morphogenetic protein. Oncogene, 21, 7156-7163.
9. Cameron,E.R. et al. (2003) The Runx genes as dominant oncogenes. Blood Cells Mol. Dis., 30, 194-200.
10. Ito,Y. et al. (2003) RUNX and cancer. Ann. Acad.Med. Singapore, 32, S6-S7.
11. Ge,C. et al. (2009) Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. J. Biol. Chem., 284, 32533-32543.
12. Guo,H. et al. (2007) Smad4 and ERK2 stimulated by transforming growth factor beta1 in rhabdomyosarcoma. Chin. Med. J. (Engl.), 120, 515-521.
13. Javelaud,D. et al. (2006) Smad signal transduction. Interplays between the smad and map kinase signaling pathways. Protein Cell Regul., 5, 317-334.
14. Wendel,H.G. et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature, 428, 332-337.
15. Berkel,H.J. et al. (2001) Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol. Biomarkers Prev., 10, 663-666.
16. Rajasekhar,V.K. et al. (2004) Postgenomic global analysis of translational control induced by oncogenic signaling. Oncogene, 23, 3248-3264.
17. Durst,K.L. et al. (2004) Role of RUNX family members in transcriptional repression and gene silencing. Oncogene, 23, 4220-4224.
18. Slattery,M.L. et al. (1997) Dietary fats and colon cancer: assessment of risk associated with specific fatty acids. Int. J. Cancer, 73, 670-677.
19. Slattery,M.L. et al. (2003) Energy balance and rectal cancer: an evaluation of energy intake, energy expenditure, and body mass index. Nutr. Cancer, 46, 166-171.
20. Slattery,M.L. et al. (1997) Energy balance and colon cancer-beyond physical activity. Cancer Res., 57, 75-80.
21. Slattery,M.L. et al. (2003) Physical activity and colorectal cancer. Am. J. Epidemiol., 158, 214-224.
22. Edwards,S. et al. (1994) Objective system for interviewer performance evaluation for use in epidemiologic studies. Am. J. Epidemiol., 140, 1020-1028.
23. Samowitz,W.S. et al. (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer, 99, 597-602.
24. Slattery,M.L. et al. (2000) Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J. Natl Cancer Inst., 92, 1831-1836.
25. Samowitz,W.S. et al. (2000) Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol. Biomarkers Prev., 9, 1193-1197.
26. Slattery,M.L. et al. (2007) Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int. J. Cancer, 120, 656-663.
27. Slattery,M.L. et al. (2009) A comparison of colon and rectal somatic DNA alterations. Dis. Colon Rectum, 52, 1304-1311.
28. Conneely,K.N. et al. (2007) So many correlated tests, so little time! rapid adjustment of P values for multiple correlated tests. Am. J. Hum. Genet., 81, 1158-1168.
29. Gordon,K.J. et al. (2008) Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim. Biophys. Acta, 1782, 197-228.
30. Korchynskyi,O. et al. (1999) Expression of Smad proteins in human colorectal cancer. Int. J. Cancer, 82, 197-202.
31. Subramaniam,M.M. et al. (2009) RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am. J. Gastroenterol., 104, 426-436.
32. Subramaniam,M.M. et al. (2009) Molecular pathology of RUNX3 in human carcinogenesis. Biochim. Biophys. Acta, 1796, 315-331.
33. Wu,G.S. (2007) Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev., 26, 579-585.
34. Vial,E. et al. (2003) Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J. Cell Sci., 116, 4957-4963.
35. Waddington,C. (1942) Canalization of development and the inheritance of acquired characteristics. Nature, 150, 563-565.
36. Barkai,N. et al. (1997) Robustness in simple biochemical networks. Nature, 387, 913-917.
37. Potter,J.D. (2007) Morphogens, morphostats, microarchitecture and malignancy. Nat. Rev. Cancer, 7, 464-474.
38. Baker,S.G. et al. (2009) Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats. BMC Cancer, 9, 89.
39. Baker,S.G. et al. (2010) Research on early-stage carcinogenesis: are we approaching paradigm instability? J. Clin. Oncol., 28, 3215-3218.